Clinic
Alegent Creighton Health
Alegent Creighton Health was paid $4.26M by Medicaid between Jan 2018 and Dec 2024, across 120 billing codes. Its largest line is 99284, emergency room visit (serious) — 20% of everything it billed.
33Billing provider infoALEGENT CREIGHTON HEALTH
OMAHA, NE 68130
OMAHA, NE 68130
33aNPI1649355132assigned 10/25/2006
33bProvider typeAmbulatory Surgical Clinic/Center
28Total paid$4.26M
24GClaims150,310
24DCodes billed120
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Ambulatory Surgical Clinic/Center providers in Nebraska
Rank by total paid#6 of 35
Median peer was paid$190K
This provider vs. median22×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official KUIPER, EVERT controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 15,912 | $628K | |
| 2019 | 15,731 | $620K | |
| 2020 | 17,254 | $558K | |
| 2021 | 39,830 | $845K | |
| 2022 | 42,177 | $1.01M | |
| 2023 | 16,450 | $483K | |
| 2024incomplete | 2,956 | $113K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 20% | 5,967 | 5,340 | $846K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 5,220 | 4,825 | $637K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 9.7% | 3,003 | 2,636 | $412K |
| 96361 | Intravenous infusion, hydration; each additional hour | 9.4% | 2,587 | 1,697 | $399K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 8.1% | 5,369 | 1,750 | $347K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 7.6% | 1,319 | 1,205 | $323K |
| 70450 | Computed tomography, head or brain; without contrast material | 5.3% | 1,443 | 1,279 | $225K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 2.3% | 1,073 | 946 | $100K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.3% | 1,202 | 898 | $98K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 2.1% | 2,077 | 747 | $91K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 804 | 751 | $61K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.1% | 337 | 152 | $47K |
108 more codes
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 4,269 | $41K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 769 | $36K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 54 | $35K |
| 80050 | General health panel | <1% | 2,509 | $34K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 142 | $32K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 367 | $30K |
| G0378 | Hospital observation service, per hour | <1% | 1,047 | $30K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 942 | $28K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 3,882 | $28K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 581 | $27K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 4,043 | $24K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 3,044 | $24K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 260 | $20K |
| J3490 | Unclassified drugs | <1% | 14,957 | $19K |
| 80053 | Comprehensive metabolic panel | <1% | 6,443 | $18K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,001 | $17K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 7,531 | $14K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 815 | $14K |
| 97165 | <1% | 317 | $11K | |
| 84484 | <1% | 3,512 | $11K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 720 | $10K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,086 | $9K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 44 | $9K |
| 96376 | <1% | 1,236 | $9K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,649 | $9K |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,751 | $8K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 500 | $8K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 1,598 | $8K |
| J2704 | Injection, propofol, 10 mg | <1% | 2,631 | $8K |
| 83690 | <1% | 2,707 | $7K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,256 | $7K |
| 59025 | Fetal non-stress test | <1% | 84 | $7K |
| 76642 | <1% | 45 | $6K | |
| 71045 | Radiologic examination, chest; single view | <1% | 1,899 | $6K |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,356 | $6K |
| 81025 | <1% | 1,940 | $6K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 762 | $5K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,080 | $5K |
| 81001 | <1% | 2,387 | $4K | |
| 97161 | <1% | 860 | $3K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,629 | $3K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 63 | $3K |
| 82962 | <1% | 2,643 | $3K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 169 | $3K |
| 83605 | <1% | 1,202 | $2K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 755 | $2K |
| 81003 | <1% | 1,941 | $2K | |
| 85610 | <1% | 1,172 | $2K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,441 | $2K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 16 | $2K |
| 93971 | <1% | 13 | $1K | |
| 84703 | <1% | 614 | $1K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 178 | $1K |
| 85730 | <1% | 229 | $1K | |
| 71250 | <1% | 13 | $1K | |
| A4649 | Surgical supply; miscellaneous | <1% | 372 | $1K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 95 | $945.21 |
| 94760 | <1% | 108 | $813.32 | |
| 97113 | <1% | 31 | $784.79 | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 5,236 | $689.95 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 293 | $653.70 |
| A9270 | Non-covered item or service | <1% | 2,882 | $430.39 |
| 86140 | <1% | 200 | $327.97 | |
| 87081 | <1% | 42 | $321.64 | |
| 74018 | <1% | 13 | $294.37 | |
| 90715 | <1% | 12 | $274.52 | |
| 85379 | <1% | 418 | $267.01 | |
| 83735 | <1% | 709 | $192.12 | |
| 83880 | <1% | 450 | $174.63 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 107 | $155.16 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 12 | $145.87 |
| 73630 | <1% | 17 | $140.24 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 231 | $126.40 |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 96 | $105.97 |
| 86900 | <1% | 14 | $99.80 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 1,305 | $89.00 |
| 73610 | <1% | 17 | $71.53 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 33 | $42.70 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 599 | $40.64 |
| 80143 | <1% | 279 | $30.46 | |
| 84702 | <1% | 29 | $28.48 | |
| 82077 | <1% | 693 | $27.42 | |
| 87040 | <1% | 209 | $23.04 | |
| 80179 | <1% | 256 | $15.24 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 170 | $14.93 |
| 87070 | <1% | 17 | $10.49 | |
| 87186 | <1% | 15 | $10.48 | |
| 87077 | <1% | 16 | $10.48 | |
| 85027 | <1% | 20 | $8.11 | |
| 87205 | <1% | 32 | $5.24 | |
| 86901 | <1% | 14 | $2.99 | |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 46 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 83 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 33 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 29 | $0.00 |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | 0% | 16 | $0.00 |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 16 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 137 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 97 | $0.00 |
| 97162 | 0% | 42 | $0.00 | |
| 88342 | 0% | 34 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 12 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 14 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 71 | $0.00 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 30 | $0.00 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 0% | 18 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 19 | $0.00 |
| C1889 | Implantable/insertable device, not otherwise classified | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKUIPER, EVERT (CHI HEALTH CEO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.